1. Home
  2. LOOP vs ACET Comparison

LOOP vs ACET Comparison

Compare LOOP & ACET Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Loop Industries Inc.

LOOP

Loop Industries Inc.

N/A

Current Price

$0.26

Market Cap

39.7M

Sector

Industrials

ML Signal

N/A

ACET

Adicet Bio Inc.

N/A

Current Price

$3.41

Market Cap

33.5M

Sector

Health Care

ML Signal

N/A

Company Overview

Basic Information
Metric
LOOP
ACET
Founded
2010
1947
Country
Canada
United States
Employees
N/A
102
Industry
Major Chemicals
Biotechnology: Pharmaceutical Preparations
Sector
Industrials
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
39.7M
33.5M
IPO Year
2010
2017

Fundamental Metrics

Financial Performance
Metric
LOOP
ACET
Price
$0.26
$3.41
Analyst Decision
Buy
Strong Buy
Analyst Count
2
6
Target Price
$2.30
★ $34.83
AVG Volume (30 Days)
104.6K
★ 187.5K
Earning Date
10-15-2026
11-13-2026
Dividend Yield
N/A
N/A
EPS Growth
★ 27.27
N/A
EPS
★ N/A
N/A
Revenue
★ $10,889,000.00
N/A
Revenue This Year
$63.62
N/A
Revenue Next Year
$735.32
N/A
P/E Ratio
★ N/A
N/A
Revenue Growth
★ 7016.99
N/A
52 Week Low
$0.24
$0.46
52 Week High
$1.73
$9.97

Technical Indicators

Market Signals
Indicator
LOOP
ACET
Relative Strength Index (RSI) 32.42 18.83
Support Level N/A N/A
Resistance Level $0.48 $9.59
Average True Range (ATR) 0.03 0.34
MACD -0.00 -0.02
Stochastic Oscillator 17.75 3.39

Price Performance

Historical Comparison
LOOP
ACET

About LOOP Loop Industries Inc.

Loop Industries Inc is a technology company whose mission is to accelerate the world's shift toward sustainable PET plastic and polyester fiber and away from dependence on fossil fuels. Loop Industries owns patented and proprietary technology that depolymerizes no and low-value waste PET plastic and polyester fiber, including plastic bottles, packaging, and textiles such as carpets and clothing, into its base building block monomers, DMT and MEG.

About ACET Adicet Bio Inc.

Adicet Bio Inc is a clinical-stage biotechnology company discovering and developing allogeneic gamma delta T cell therapies for autoimmune diseases and cancer. It is advancing a pipeline of off-the-shelf gamma delta T cells, engineered with chimeric antigen receptors (CARs), to facilitate durable activity in patients. The company's main product candidate, prulacabtagene leucel (prula-cel), is an allogeneic gamma delta T cell therapy expressing a CAR targeting CD20, and is being developed for the potential treatment of autoimmune diseases. Additionally, it is pursuing ADI-212, a next-generation gene-edited and armored clinical candidate designed to target prostate-specific membrane antigen (PSMA).

Share on Social Networks: